SOLICITATION NOTICE
65 -- Pediatric Flu Vaccines 2013/2014
- Notice Date
- 8/20/2013
- Notice Type
- Justification and Approval (J&A)
- NAICS
- 325412
— Pharmaceutical Preparation Manufacturing
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Archive Date
- 9/13/2013
- Point of Contact
- Berta Biltz, Phone: 770-488-2643, Alan W Sims, Phone: 770-488-2896
- E-Mail Address
-
boh9@cdc.gov, auy0@cdc.gov
(boh9@cdc.gov, auy0@cdc.gov)
- Small Business Set-Aside
- N/A
- Award Number
- 200-2013-54015
- Award Date
- 2/22/2013
- Description
- The Centers for Disease Control and Prevention(CDC), National Center for Immunization and Respiratory Diseases, Immunization Services Division, Vaccine Supply and Assurance Branch contemplates issuing a Modification is to Contract No. 200-2013-54015 with Sanofi Pasteur of Swiftwater PA to include Fluzone® Quadrivalent Pediatric vaccine (NDC 49281-0513-25), for use in children ages 6 to 35 months; The maximum ordering quantity under the contract will be 200,000 doses. Several of CDC's vaccine contracts are limited to seasonal influenza vaccines. Beginning this influenza season, the FDA has licensed a new type of flu vaccine product, which contains 4 strains rather than 3 strains. These 4-strain flu vaccines, referred to as quadrivalent vaccines, offer additional protection against circulating influenza viruses. Since the time that CDC's pediatric influenza vaccine contracts were awarded in February 2013, quadrivalent inactivated pediatric influenza vaccine indicated for children ages 6 to 35 months was approved by the FDA. This product is currently produced by only a single US-licensed manufacturer: Sanofi Pasteur. Therefore, Sanofi Pasteur is considered to be the only source that can satisfy this requirement. However, all responsible sources who can provide the same product and wished to be considered by the CDC may email a description of their FDA approved product to bbiltz@cdc.gov by Noon, EST/DST, and September 4, 2013. The anticipated period of performance is September 13, 2013 to February 1, 2014. The anticipated date of award is September 12, 2013. All questions/concerns about this announcement shall be submitted via e-mail to BBiltz@cdc.gov. It is your responsibility to keep up with additional postings regarding this announcement on the Fedbizopps Website.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/7290297da94754347f72a3858fac9838)
- Place of Performance
- Address: SWIFTWATER, Pennsylvania, United States
- Record
- SN03155819-W 20130822/130821000136-7290297da94754347f72a3858fac9838 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |